CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sweden's Nanexa Q3 revenue surges on Novo license deal

By Reuters News


Overview

  • Sweden drug delivery tech firm's Q3 revenue surged yr/yr after Novo license deal

  • Q3 EPS turned positive from a loss a year earlier

  • Company signed EUR 1.165 bln global license and collaboration deal with Novo


Outlook

  • Nanexa says collaborations aim to advance large-scale manufacturing for PharmaShell programs

  • Company expects future milestone and royalty payments from Novo collaboration as projects advance


Result Drivers

  • NOVO LICENSE DEAL - Q3 results driven by upfront payment from global license and collaboration agreement with Novo for long-acting injectables

  • MANUFACTURING PARTNERSHIP - Joint development agreement with Forge Nano to advance large-scale manufacturing of ALD-coated injectables


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

SEK 227.87 mln

Q3 EPS

SEK 0.80

Q3 Net Income

SEK 157.38 mln

Q3 EBIT

SEK 157.33 mln


Analyst Coverage

  • The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 32 three months ago


Reuters Recommended Reads

  • Nov 4 - Novo Nordisk Q3 adjusted profit, sales jump on GLP-1 demand; raises outlook

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

  • Nov 4 - Revolution Medicines Q3 revenue reaches $198 mln after RASONQUE launch


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.